Navigation Links
Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
Date:10/5/2009

idates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended July 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                          Media
    info@peregrineinc.com                              Barbara Lindheim
    (800) 987-8256                                     (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 24, 2014 This research ... PBS, Starch Based Plastics, Regenerated Cellulose, PCL), by ... Trends and Forecasts to 2019”, defines and segments ... and forecast of its global volume and value. ... Figures spread through 178 Slides and in-depth TOC ...
(Date:10/25/2014)... , October 24, 2014 Oramed ... pharmaceutical company focused on the development of oral drug ... Nadav Kidron will present at FireRock Capital,s Micro-Cap ... Annual Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ,Time: ... New York City , ...
(Date:10/25/2014)... 24, 2014 ... has announced the addition of the  "The ... Other 2-D Nanomaterials "  report to their ... ,CNTs and graphene are the strongest, lightest ... with a performance-per-weight greater than any other ...
(Date:10/22/2014)... The North American crystal oscillator market report ... analysis and forecast of revenue. This market was valued ... reach $623.6 million by 2018, at a CAGR of ... TOC of the North American crystal oscillator market report, ... This also provides a glimpse of the segmentation of ...
Breaking Biology Technology:Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4
... Introduction ... traditional DNA sequencing systems, sequencing products are radioactively labeled ... radiolabeled dNTPs during primer extension. Successful sequencing results produced ... template quality. DNA containing nicks, breaks, impurities or high ...
... , A sensitive and ... is presented for a simultaneous analysis of the metabolites of ... Abstract , ... by homogenization, organic solvent washes, hydrolysis and derivatization followed by ...
... Furazolidone, Furaltadone, Nitrofurazone and Nitrofurantoine belong to the group ... of gastrointestinal infections in cattle and poultry. Due to ... furazolidone) was prohibited in 1993 in the European Union ... in the European animal breeding (VO (EWG) No. 1441/95). ...
Cached Biology Technology:A simple method to sequence from bacterial colonies using [a-33P] radiolabeled ddNTPs and Thermo Sequenase 2A simple method to sequence from bacterial colonies using [a-33P] radiolabeled ddNTPs and Thermo Sequenase 3High sensitivity quantitation of metabolites of nitrofuran antibiotics in animal tissue using LC/MS/MS 2High sensitivity quantitation of metabolites of nitrofuran antibiotics in animal tissue using LC/MS/MS 3Detection of nitrofurane metabolites in food with HPLC/MS/MS 2
(Date:10/25/2014)... , Oct. 23, 2014 Research ... "Biometrics Market in Europe 2014-2018" report to their ... helps to assess individuals on the basis of their ... identification of both physiological traits such as fingerprints, face ... and behavioral traits such as keystroke patterns and speech ...
(Date:10/22/2014)... SAN JOSE, Calif. , Oct. 20, 2014 /PRNewswire/ ... with the United States Air Force Research Laboratory (AFRL), ... for Integrative Medicine (AzCIM) at the University of Arizona ... to receive research funding.  The AzCIM project,s goal is ... their ability to collect different volumes of sweat under ...
(Date:10/22/2014)... Mass., Oct. 21, 2014 Aware, Inc. (NASDAQ: ... services, today reported financial results for its third quarter ended ... of 2014 was $6.0 million, an increase of 40% compared ... income in the third quarter of 2014 was $4.1 million ... Higher operating income in the current three month period was ...
Breaking Biology News(10 mins):Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7
... Most previous studies have indicated that people in cities ... the country. By using more complex methods of analysis than ... discovered that people,s carbon emissions are practically the same in ... else, CO 2 emissions that cause climate change are ...
... Highlights: Advanced technologies create high-capacity ... was integrated easily with Army,s cellular biometric network ... Harris Corporation,s (NYSE: HRS ) ... for various mission scenarios at the Empire Challenge 2011 , ...
... being hunted to local extinction more than a century ago ... right whales of mainland New Zealand are coming home. ... time that whales from a small surviving population around remote, ... Zealand mainland. Before the onslaught of 19th century whaling, ...
Cached Biology News:City dwellers produce as much CO2 as countryside people do 2Harris Corporation's Highband Networking Radio Provides Mobile, Wideband Communications for Empire Challenge 2011 2Harris Corporation's Highband Networking Radio Provides Mobile, Wideband Communications for Empire Challenge 2011 3Fighting back from extinction, New Zealand right whale is returning home 2Fighting back from extinction, New Zealand right whale is returning home 3
... The CopyControl™ vector can be induced prior ... vectors provide the stability of single-copy BACs ... or other cloning vectors. The kits provide ... reagents, insert size screening system) necessary to ...
...
... style strip holder is designed for use ... This CLS number is a new product ... number. If showing no availability yet, please ... or contact customer service for assistance. ID ...
Designed for use with all 96-well SPRI reagent kits. Used with round bottom 96-well microplates, and 96-well thermal cycling plates....
Biology Products: